(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Holger Palmedo reported results of the PARABO cohort (NCT02398526), a prospective, observational, noninterventional, single-arm study evaluating pain efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Radium-223 in German real-life nuclear medicine settings.